Skip to content

Faeth Therapeutics

US · FTH #3576 by market cap Listed 2021
7.88 -0.81 -9.32%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 8.51 -2.07%
After-hours 7.88 0.00%
40.057.887.882026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on FTH?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -43.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 10.6% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Return on equity -74.0% Better than 7%
Return on invested capital -71.5% Better than 4%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -75.4% Better than 1%
6-month return -55.7% Better than 6%
12-month return (ex latest month) 95.8% Better than 95%
Distance below 52-week high 81.3% Better than 2%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.1x Better than 86%
Debt to assets 6.6% Better than 76%
Interest coverage -657.9x Better than 2%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 633.2% Better than 100%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -21.44%
1M -62.10%
3M -75.45%
6M -55.18%
YTD -26.15%
1Y -10.45%
3Y -36.45%
5Y -95.34%

Key statistics

Price & volume

Prev close
8.69
Open
8.52
Day range
7.84 - 9.13
Avg price
8.26
Volume
419.11K
Turnover
3.46M
Amplitude
14.87%
52-week range
7.45 - 42.14

Valuation

P/E
-0.47
P/E (TTM)
-0.35
P/B
1.26
EPS
-16.72
Net profit
-432.11M
Net assets
161.09M

Share structure

Market cap
203.65M
Float cap
132.95M
Shares out
25.84M
Float shares
16.87M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-02-04
52-week range 1% of range
7.45 42.14

81.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+9.14K net over the window

Short interest

Shares short
2.73M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Faeth Therapeutics (FTH)?

Faeth Therapeutics last traded at 7.88. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Faeth Therapeutics's market cap?

About 203.65M.

What is the P/E ratio of Faeth Therapeutics?

The trailing twelve-month P/E is -0.35. The Valuation tab shows it against the stock's own five-year range.

Does Faeth Therapeutics pay a dividend?

Faeth Therapeutics does not currently pay a regular dividend.

Is Faeth Therapeutics a buy according to analysts?

The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 57.78, which implies 633.2% upside from the current price. This is not investment advice.

What is Faeth Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Faeth Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.

Faeth Therapeutics discussion 0 comments

Add a comment